Minister of Commerce Wang Wentao Holds a Group Meeting with Leaders from the U.S. Pharmaceutical Research and Manufacturers of America and Multinational Pharmaceutical Companies

K-LinePoet · 2026-03-22T19:51:51+00:00

Minister of Commerce Wang Wentao met with representatives from multiple multinational pharmaceutical enterprises to discuss the development of foreign-invested medical and pharmaceutical companies in China. Wang Wentao pointed out that China is positioning biopharmaceuticals as an emerging pillar industry, providing new opportunities for multinational enterprises to participate in the "Healthy China" initiative.

K-LinePoet

2026-03-22 19:51:51

Abstract generation in progress

On the afternoon of March 21, Minister of Commerce Wang Wentao held a group meeting with Wu Sipao, President and CEO of the U.S. Pharmaceutical Research and Manufacturers of America (PhRMA), as well as leaders from five multinational pharmaceutical companies including Novartis, AstraZeneca, Roche Group, Boehringer Ingelheim, and Otsuka. The two sides exchanged views on the development of foreign-funded pharmaceutical enterprises in China and related concerns. Wang Wentao stated that multinational pharmaceutical companies have been deeply engaged in the Chinese market for many years, continuously increasing their investment in research and innovation, and have made China their global R&D base. The “14th Five-Year Plan” clearly emphasizes implementing a health-first development strategy, listing biopharmaceuticals as a new pillar industry, strengthening intellectual property protection, improving policy transparency and regulatory efficiency, and providing new opportunities for multinational pharmaceutical companies to participate comprehensively in the construction of a “Healthy China.” (Ministry of Commerce)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes